The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MENSCH
- 12 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated